Clinical trials: Buprenorphine
Opioid-Related Disorders
Buprenorphine Dosing Interval - 5
The purpose of this study is to explore the feasibility of extending the dosing interval of well maintained buprenorphine patients to 48 and 72 hours, leading to eventual 3 times/week dosing.
- Trial name
- NCT00000209
- Testing
- Buprenorphine
- Where
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)
Opioid Abuse and Addiction
Innovatively Increasing PCP Prescribing of Buprenorphine: Measurement Based Care and Integrated Electronic Solution
The objective of this observational feasibility project is to assess the feasibility and acceptability of universal screening and measurement based care for opioid use disorder (OUD) utilizing a computer software program in a…
- Trial name
- MBC4OUD (NCT04059016)
- Testing
- MBC4OUD
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Pain, Depression
Treating Chronic Pain in Buprenorphine Patients in Primary Care Settings
Individuals will be recruited by posted advertisements in the waiting rooms of the PCP offices and by physician referral. After an initial phone screen, research staff will meet with interested individuals in their PCP offices…
- Conditions
- Pain, Depression, Substance Use
- Trial name
- BupPain (NCT01752998)
- Testing
- Treating Opioid Patients' Pain and Sadness (TOPPS), Health Education
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Butler Hospital
Opioid Use Disorder
Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial
The goal of this pilot study is to test novel, adjunctive pharmacotherapy for patients with opioid use disorder (POUD) who may be at risk for overdose and other poor opioid use disorder (OUD) outcomes even after initiating…
- Trial name
- DEMURE (NCT07148206)
- Testing
- Dronabinol Capsules, Epidiolex 100 mg/mL Oral Solution
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Montefiore Medical Center
Cocaine Abuse
ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine
The purpose of this study is to assess the safety and tolerability of ALKS33-BUP when administered to opioid-experienced cocaine abusers.
- Trial name
- NCT01366001
- Testing
- ALKS 33-BUP, ALKS 33
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Alkermes, Inc.
Opioid Dependence
Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence
Buprenorphine (BPN) is an approved treatment for opioid dependence; however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low.
- Trial name
- PRO-807 (NCT00630201)
- Testing
- Probuphine (buprenorphine implant)
- Where
- 15 sites in United States
- Volunteers
- 62 people
- Sponsor
- Titan Pharmaceuticals
Opioid-Related Disorders
Buprenorphine Detoxification With Two Types of Treatment. BBD IV - 13
The purpose of this study is to evaluate buprenorphine and behavioral treatment with and without contingent payment on compliance with pro-social activities.
- Trial name
- NCT00000231
- Testing
- Buprenorphine
- Where
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)
Opiate Dependence, Substance-related Disorders
Prescription Opioid Addiction Treatment Study (POATS)
The purpose of this study is to determine whether treatment outcome for subjects dependent on prescription opioid analgesics can be improved by adding individual drug counseling to the prescription of buprenorphine/naloxone with…
- Conditions
- Opiate Dependence, Substance-related Disorders, Opioid-related Disorders
- Trial name
- NCT00316277
- Testing
- Standard Medical Management (SMM) of Prescription Opiate Abuse, Enhanced Medical Management (EMM) of Prescription Opiate Abuse
- Where
- 12 sites in United States
- Volunteers
- 653 people
- Sponsor
- Mclean Hospital
Heroin Dependence, Opioid-Related Disorders
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4
The purpose of this study is to assess the abuse liability and examine the reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in buprenorphine-naloxone maintained volunteers
- Trial name
- NCT00000329
- Testing
- Opioid-Related Disorders
- Where
- United States
- Sponsor
- University of Colorado, Denver
HIV Infections, Heroin Dependence
Directly Administered Antiretroviral Therapy (DAART) Among HIV-1infected Injecting Drug Users (IDUs) in Chennai, India
Though the HIV epidemic in India is predominantly among heterosexual populations, it is estimated that there are approximately 1.1 million injection drug users (IDUs) in India with HIV prevalence as high as 64% among IDUs in…
- Trial name
- DAART+ (NCT00709007)
- Testing
- Directly Administered Antiretroviral Therapy (DAART), SAT
- Where
- India
- Sponsor
- Johns Hopkins University
Opioid-Related Disorders, Behavior, Addictive
Adolescent Community Reinforcement Approach in Combination With Buprenorphine/Naloxone for Severe Opioid Use
The study assesses whether adding a behavioral intervention, known as the Adolescent Community Reinforcement Approach (A-CRA), to the treatment of individuals already receiving buprenorphine/naloxone can improve treatment success…
- Trial name
- A-CRA/MAT (NCT03287180)
- Testing
- Adolescent Community Reinforcement Approach (A-CRA), Combination of buprenorphine/naloxone 4/1
- Sponsor
- Emory University
Heroin Dependence
Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals
A short-term treatment with buprenorphine prior to initiating treatment with naltrexone may increase the proportion of heroin-dependent patients successfully inducted onto Vivitrol.
- Trial name
- NCT03711318
- Testing
- Buprenorphine/naloxone
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Pain
Randomized, Double-Blind Cross-Over Trial Of Buprenorphine and Low-Dose Naloxone Versus Buprenorphine
This study compares two medications for analgesic potency and side effects in a sample of individuals with moderate pain. After screening, eligible participants will be randomly assigned to begin blinded treatment with one of two…
- Trial name
- NCT00679458
- Testing
- buprenorphine and low-dose naloxone, buprenorphine alone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, Los Angeles
Opioid-use Disorder, Neonatal Abstinence Syndrome
MOM NEST Study: Maternal Opioid Medication: Naltrexone Efficacy Study
This is a multi-center prospective comparative cohort study examining the safety, efficacy, pharmacokinetics, and pharmacogenomics of naltrexone for pregnant women with opioid use disorder.
- Conditions
- Opioid-use Disorder, Neonatal Abstinence Syndrome, Pregnancy, High Risk, Alcohol Use Disorder
- Trial name
- NCT03718104
- Testing
- Pharmacokinetic analysis, Safety and Efficacy, Genetic and epigenetic analysis
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Boston Medical Center
Pain
Buprenorphine vs. Opioid Dose Escalation Among Patients With Chronic Pain
This study compares buprenorphine/naloxone to opioid dose escalation among patients with poorly controlled non-cancer pain on 30-100 mg daily morphine equivalent opioid dose.
- Trial name
- Bup (NCT01875848)
- Testing
- buprenorphine/naloxone, opioid dose escalation
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- VA Office of Research and Development
Opiate Substitution Treatment
Extended-release Pharmacotherapy for Opioid Use Disorder
The primary objective is a clinical superiority effectiveness contrast to standard of care. Reported following SPIRIT and CONSORT standards, the study will determine whether extended-release injectable depot Buprenorphine…
- Trial name
- EXPO (NCT05164549)
- Testing
- Buprenorphine Injectable Product, Methadone, Buprenorphine
- Where
- 5 sites in United Kingdom
- Volunteers
- 342 people
- Sponsor
- King's College London
Opioid Dependence
The Safety of Using Buprenorphine With Naloxone in a Buccal Film to Initiate Treatment of Opioid Dependent Subjects
A randomized, double blind, active controlled study in approximately 40 opioid dependent subjects. Study duration is up to five days and includes a maximum of 3 days confinement in the clinic.
- Trial name
- NCT02516436
- Testing
- BEMA Buprenorphine NX, Buprenorphine
- Where
- 3 sites in United States
- Sponsor
- BioDelivery Sciences International
Low Back Pain
Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Naive Subjects
The purpose of this study is to determine if buprenorphine hydrochloride (HCl) buccal film is effective in treating opioid-naive subjects, with moderate to severe chronic low back pain (CLBP), who require continuous…
- Trial name
- NCT01633944
- Testing
- Buprenorphine
- Where
- 60 sites in United States
- Volunteers
- 752 people
- Sponsor
- BioDelivery Sciences International
Pain, Osteoarthritis
Effects of Low Dose Buprenorphine on Recovery After Hip or Knee Arthroplasty
Buprenorphine is a highly lipophilic thebaine derivative that appears to have high affinity for mu-, kappa-, and delta-opioid receptors and low affinity for opioid receptors like 1 -receptors.
- Trial name
- lonkkalaasta (NCT02575664)
- Testing
- Buprenorphine
- Where
- Finland
- Volunteers
- 160 people
- Sponsor
- Kuopio University Hospital
Pain
Intravenous Buprenorphine Versus Morphine for Severe Pain in the Emergency Department
This study evaluates intravenous (IV) buprenorphine versus IV morphine for the management of severe, acute pain among emergency department (ED) patients.
- Trial name
- NCT03256487
- Testing
- Buprenorphine, Morphine Sulfate
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Alameda Health System